Pharmaceutical News

RSS

FDA approves Istodax for treatment of Cutaneous T-cell Lymphoma

The U.S. Food and Drug Administration has approved Istodax (romidepsin), an injectable medication, for treatment of patients with a rare form of cancer known as Cutaneous T-cell Lymphoma (CTCL).

10 Nov 2009

European Union funds a three-year project to establish a research network for complementary medicine study

A three-year project called CAMbrella will receive nearly 1.5 million euros of European Union funding to establish a research network for the study of complementary medicine. The Center for Naturopathic Research at "Rechts der Isar," the university hospital of the Technische Universitaet Muenchen will coordinate the project for the winning applicant group, which includes 16 scientific organizations from 12 European countries.

10 Nov 2009

FDA accepts ChemGenex Pharmaceuticals' NDA for Omapro

ChemGenex Pharmaceuticals Limited announced today that the U.S. Food & Drug Administration (FDA) has accepted the company’s New Drug Application (NDA) for Omapro™ (omacetaxine mepesuccinate) for the treatment of patients with chronic myeloid leukemia (CML) who have failed treatment with imatinib and who have developed the Bcr-Abl T315I mutation.

10 Nov 2009

Diabetic Care Services responds to NRF's updated “Buyer Beware” list

Diabetic Care Services responds to the National Retail Federation’s updated “Buyer Beware” list with tips on avoiding fraudulent diabetes supplies. The NRF updated its list of common household items, including diabetes supplies, sold on online auction sites that are at risk of being stolen or tainted.

10 Nov 2009

TRICARE South Region beneficiaries urged to get H1N1 influenza vaccinations

Humana Military Healthcare Services, a wholly-owned subsidiary of Humana Inc. (NYSE: HUM), encourages TRICARE South Region beneficiaries to get their H1N1 influenza vaccinations in an effort to reduce the spread of the virus. Anticipating a greater need for the shots, the Department of Defense (DoD) is encouraging all military personnel to obtain the vaccines.

9 Nov 2009

VaxInnate licensed to use 3M Drug Delivery Systems' TLR agonists

3M Drug Delivery Systems has signed an agreement with VaxInnate Corporation under which VaxInnate acquires the use of 3M’s patented toll-like receptor (TLR) agonists for use as vaccine adjuvants. Data suggest that 3M’s TLR agonists could enhance vaccine potency, potentially enabling VaxInnate to develop vaccines that provide faster, more robust protection.

9 Nov 2009

Scientific article supports AEterna Zentaris' development of perifosine inhibitor

AEterna Zentaris Inc., a global biopharmaceutical company focused on endocrine therapy and oncology, today announced publication of a scientific article in the renowned Journal of Urology, supporting the development of the Company's PI3K/Akt pathway inhibitor oral compound, perifosine, for the treatment of cancer.

9 Nov 2009

Shire's INTUNIV for treating ADHD now available in the U.S.

Shire plc, the global specialty biopharmaceutical company, today announced the availability of INTUNIV(TM) (guanfacine) Extended Release Tablets in pharmacies across the United States for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents ages 6 to 17.

9 Nov 2009

Covidien contraindicates use of its Optimark gadoversetamide injection

Covidien, a leading global provider of healthcare products, today announced that it will voluntarily contraindicate the use of its Optimark™ gadoversetamide injection, a gadolinium-based contrast agent (GBCA), in magnetic resonance imaging (MRI) procedures involving patients with severe renal impairment.

9 Nov 2009

Enzon Announces to sell its specialty pharmaceutical business to the sigma-tau Group for $300 million

Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced that it has entered into a definitive agreement to sell its specialty pharmaceutical business to the sigma-tau Group for $300 million plus an additional amount of up to $27 million based on success milestones. Enzon will also receive royalties of 5 to 10 percent on incremental net sales above a 2009 baseline amount from Enzon’s four marketed specialty pharmaceutical products through 2014.

9 Nov 2009

Ikano Therapeutics' midazolam granted Orphan Drug designation

Ikano Therapeutics, Inc. announced today that it has received Orphan Drug designation for midazolam in the acute treatment of certain forms of epileptic seizure known as cluster seizures or alternatively, as acute repetitive seizures.

9 Nov 2009

CRINONE vaginal progesterone gel as effective as IM progesterone for luteal phase support in IVF-ET

In their American Society of Reproductive Medicine (ASRM) conference wrap-up, Medscape highlighted the article published by them on October 27, 2009, which summarized the results from the largest prospective, randomized clinical study to compare vaginal progesterone to intramuscular progesterone injections (IM progesterone) for luteal support in infertility treatment.

9 Nov 2009

Decision Resources forecasts sales of HER2-targeting agents to grow by 3.3% per year

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in 2008, human epidermal growth factor receptor 2 (HER2) targeting therapies -- which include Roche/Chugai's Herceptin and GlaxoSmithKline/Nippon Kayaku's Tykerb/Tyverb -- were the highest-selling drug class in breast cancer treatment.

9 Nov 2009

Simcere Pharmaceutical Group signs agreement to acquire manufacturing license from Tianjin Tianda Pharmaceutical

Simcere Pharmaceutical Group, a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced an agreement to acquire the manufacturing license in China of Rosuvastatin from Tianjin Tianda Pharmaceutical Co., Ltd. ("Tianda").

9 Nov 2009

SuperGen to stage presentations to review clinical and non-clinical advances in different compounds

SuperGen, Inc., a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, today announced the acceptance of seven abstracts for poster presentations on November 16, 17 and 18, 2009 at the 2009 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference in Boston, MA.

9 Nov 2009

Bend Research signs collaboration agreement with Vertex Pharmaceuticals

Bend Research Inc., a company with more than 30 years of experience in applying innovative pharmaceutical technologies to help clients solve their most difficult scientific and technical problems, announced today that it has entered into a collaboration with Vertex Pharmaceuticals Incorporated, a global biotechnology company headquartered in Cambridge, MA.

9 Nov 2009

Daval International receives award for its anti-inflammatory agent AIMSPRO

Following the provision of clinical and scientific data to the US Food and Drug Administration (FDA), privately owned UK company Daval International Limited (http://www.davalinternational.com) has been informed that its innovative anti-inflammatory agent AIMSPRO(R) has been awarded an Orphan-Drug designation for the treatment of Amyotrophic Lateral Sclerosis (ALS).

9 Nov 2009

Health Canada accepts for review the EpiCept’s New Drug Submission for Ceplene

EpiCept Corporation today announced that Health Canada has accepted for review the Company’s New Drug Submission (NDS) for Ceplene® (histamine dihydrochloride) for the remission maintenance of acute myeloid leukemia (AML) patients in first complete remission.

9 Nov 2009

Betterthanmedicare.com helps plug the "donut hole", offers discounts on drugs

With his proposed health care reform plan, President Barack Obama has set his sights on cutting name-brand prescription drug costs by 50 percent for Medicare patients who fall into the "Part D" coverage gap, universally known as the "donut hole." Plan advocates rave about the potential cost-cutting and feel it's a promising start to health care reform.

7 Nov 2009

Transatlantic task force to address antibiotic resistance established, experts welcome initiative

Experts on both sides of the Atlantic applaud President Barack Obama and Swedish Prime Minister Fredrik Reinfeldt, representing the European Union (EU) Presidency, for establishing a transatlantic task force to address antibiotic resistance, an urgent and growing problem that threatens patient safety and public health worldwide.

7 Nov 2009

Pharmaceutical News

FDA approves Istodax for treatment of Cutaneous T-cell Lymphoma

European Union funds a three-year project to establish a research network for complementary medicine study

FDA accepts ChemGenex Pharmaceuticals' NDA for Omapro

Diabetic Care Services responds to NRF's updated “Buyer Beware” list

TRICARE South Region beneficiaries urged to get H1N1 influenza vaccinations

VaxInnate licensed to use 3M Drug Delivery Systems' TLR agonists

Scientific article supports AEterna Zentaris' development of perifosine inhibitor

Shire's INTUNIV for treating ADHD now available in the U.S.

Covidien contraindicates use of its Optimark gadoversetamide injection

Enzon Announces to sell its specialty pharmaceutical business to the sigma-tau Group for $300 million

Ikano Therapeutics' midazolam granted Orphan Drug designation

CRINONE vaginal progesterone gel as effective as IM progesterone for luteal phase support in IVF-ET

Decision Resources forecasts sales of HER2-targeting agents to grow by 3.3% per year

Simcere Pharmaceutical Group signs agreement to acquire manufacturing license from Tianjin Tianda Pharmaceutical

SuperGen to stage presentations to review clinical and non-clinical advances in different compounds

Bend Research signs collaboration agreement with Vertex Pharmaceuticals

Daval International receives award for its anti-inflammatory agent AIMSPRO

Health Canada accepts for review the EpiCept’s New Drug Submission for Ceplene

Betterthanmedicare.com helps plug the "donut hole", offers discounts on drugs

Transatlantic task force to address antibiotic resistance established, experts welcome initiative

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News